Johnson & Johnson submits sNDA for SPRAVATO to treat depression

Johnson & Johnson is seeking approval for SPRAVATO for treatment-resistant depression with the submission of an sNDA to the US FDA.

Jul 24, 2024 - 04:00

Johnson & Johnson submits sNDA for SPRAVATO to treat depression

Johnson & Johnson is seeking approval for SPRAVATO for treatment-resistant depression with the submission of an sNDA to the US FDA.

Read the original article

Tags:

Previous Article

FDA approves Samsung Bioepis’ EPYSQLI as Soliris biosimilar

Grünenthal gains Valinor Pharma and constipation drug Movantik

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Humira’s legacy, CEO symbolism, and genomic surgery

Feb 23, 2024

STAT+: Four burning questions about the potential 85,000-worker Kaiser Permanente strike

STAT+: Four burning questions about the potential 85,00...

Sep 22, 2023

Malaysia approves additional indication for Astrazeneca’s Evusheld

Malaysia approves additional indication for Astrazeneca...

Apr 10, 2023